We are live on
!
Find out more
5VM
5AM Venture Management Portfolio holdings
AUM
$360M
1-Year Est. Return
345.76%
This Fund
S&P 500
This Quarter
Est. Return
+8.58%
1 Year Est. Return
+345.76%
3 Year Est. Return
+491.51%
5 Year Est. Return
+330.26%
10 Year Est. Return
–
AUM
$391M
AUM Growth
+$18.9M
(+5.1%)
Cap. Flow
+$55.5M
Cap. Flow
% of AUM
14.18%
Top 10 Holdings %
Top 10 Hldgs %
80.82%
Holding
26
New
5
Increased
1
Reduced
5
Closed
2
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Enliven Therapeutics
ELVN
|
+$118M |
| 2 |
KYNB
Kyntra Bio
KYNB
|
+$7.49M |
| 3 |
MRSN
Mersana Therapeutics
MRSN
|
+$6.65M |
| 4 |
SPRB
Spruce Biosciences
SPRB
|
+$5.85M |
| 5 |
Viking Therapeutics
VKTX
|
+$3.62M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
CINC
CinCor Pharma, Inc. Common Stock
CINC
|
+$60.7M |
| 2 |
SCPH
scPharmaceuticals
SCPH
|
+$11.2M |
| 3 |
Janux Therapeutics
JANX
|
+$5.88M |
| 4 |
IDEAYA Biosciences
IDYA
|
+$5.46M |
| 5 |
ISEE
IVERIC bio, Inc. Common Stock
ISEE
|
+$2.19M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Enliven Therapeutics
ELVN
$4.15B
| $127M | 32.47% |
+5,798,475
| New | +$118M |
|
2
Entrada Therapeutics
TRDA
$282M
| $63.9M | 16.35% |
4,408,379
| – | – |
|
3
Vor Biopharma
VOR
$1.16B
| $34.2M | 8.75% |
318,086
| – | – |
|
4
Rallybio
RLYB
$84.6M
| $20.7M | 5.3% |
453,841
-12,500
| -3% | -$646K |
|
5
Crinetics Pharmaceuticals
CRNX
$8.89B
| $13.8M | 3.54% |
862,286
| – | – |
|
6
Disc Medicine
IRON
$2.93B
| $12.5M | 3.19% |
588,442
| – | – |
|
|
7
IDEAYA Biosciences
IDYA
$3.41B
| $11.9M | 3.05% |
868,520
-327,778
| -27% | -$5.46M |
|
|
SCPH
8
DELISTED
scPharmaceuticals
SCPH
| $10.9M | 2.78% |
1,200,647
-1,534,205
| -56% | -$11.2M |
|
|
KYNB
9
Kyntra Bio
KYNB
$27.4M
| $10.8M | 2.77% |
23,177
+14,154
| +157% | +$7.49M |
|
|
RNAM
10
DELISTED
Avidity Biosciences
RNAM
| $10.2M | 2.61% |
665,555
| – | – |
|
11
Arvinas
ARVN
$520M
| $8.74M | 2.24% |
320,000
| – | – |
|
12
Cogent Biosciences
COGT
$6.64B
| $8.53M | 2.18% |
790,440
| – | – |
|
13
AnaptysBio
ANAB
$1.59B
| $7.78M | 1.99% |
357,733
| – | – |
|
14
Viridian Therapeutics
VRDN
$2.13B
| $7.12M | 1.82% |
280,000
-20,000
| -7% | -$641K |
|
|
ISEE
15
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
| $6.92M | 1.77% |
284,626
-100,000
| -26% | -$2.19M |
|
|
16
Viking Therapeutics
VKTX
$3.8B
| $5.83M | 1.49% |
+350,000
| New | +$3.62M |
|
|
SPRB
17
Spruce Biosciences
SPRB
$119M
| $5.22M | 1.34% |
+31,520
| New | +$5.85M |
|
|
MRSN
18
DELISTED
Mersana Therapeutics
MRSN
| $4.87M | 1.25% |
+47,400
| New | +$6.65M |
|
19
Pharvaris
PHVS
$2.25B
| $4.73M | 1.21% |
587,600
| – | – |
|
20
Q32 Bio
QTTB
$450M
| $4.67M | 1.19% |
251,996
| – | – |
|
|
PEAR
21
DELISTED
Pear Therapeutics, Inc. Class A Common Stock
PEAR
| $4.27M | 1.09% |
16,744,113
| – | – |
|
|
IMPL
22
DELISTED
Impel Pharmaceuticals Inc. Common Stock
IMPL
| $4.04M | 1.03% |
2,884,791
| – | – |
|
|
CDTX
23
DELISTED
Cidara Therapeutics
CDTX
| $1.44M | 0.37% |
56,726
| – | – |
|
24
MoonLake Immunotherapeutics
MLTX
$1.48B
| $831K | 0.21% |
+38,856
| New | +$653K |
|
|
25
Janux Therapeutics
JANX
$934M
| – | – |
-446,266
| Closed | -$5.88M |
|
Similar funds
LSC
WIP
RA
SWM
NC
MCM
KLWA
PWC
5AM Venture Management's Q1 2023 Portfolio in Review
As of Q1 2023, 5AM Venture Management held 26 positions worth $391M, up 5.1% from $372M the previous quarter. Its ten largest holdings account for 81% of the portfolio.
5AM Venture Management deployed $55.5M of net new capital in Q1 2023, opening 5 new positions and adding to 1 existing holding. Its largest new stake was Enliven Therapeutics: 5,798,475 shares worth $127M.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.
On the sell side, the largest reduction was scPharmaceuticals, an estimated $11.2M trimmed.
- 5AM Venture Management's largest Q1 2023 buy was Enliven Therapeutics: 5,798,475 shares worth $127M.
- 5AM Venture Management added most to Kyntra Bio in Q1 2023, an estimated $7.49M increase.
- 5AM Venture Management's biggest Q1 2023 reduction was scPharmaceuticals, cutting an estimated $11.2M.
- 5AM Venture Management fully exited CinCor Pharma, Inc. Common Stock in Q1 2023, selling an estimated $60.7M.
- 5AM Venture Management's ten largest holdings make up 81% of its $391M portfolio in Q1 2023.
- 5AM Venture Management opened 5 new positions and closed 2 in Q1 2023.
- 5AM Venture Management's portfolio value rose 5.1% quarter-over-quarter to $391M.
Based on 5AM Venture Management's 13F filing for Q1 2023, filed 15 May 2023.